Ponesimod-d4

• UNSPSC Description:

  Ponesimod-d4 (ACT-128800-d4) is the deuterium labeled Ponesimod (HY-10569)[1]. Ponesimod (ACT-128800) is a potent, selective and orally active agonist of S1P1, with an IC50 of 6 nM in a radioligand binding assay. Ponesimod activates S1P1-mediated signal transduction with high potency (EC50=5.7 nM). Ponesimod can protect against lymphocyte-mediated tissue inflammation[2][3][4].

• Target Antigen:

  Isotope-Labeled Compounds; LPL Receptor

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  GPCR/G Protein;Others

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Others

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1N(C2=C([2H])C([2H])=C([2H])C([2H])=C2C)/C(S/C1=C\C3=CC=C(OC[C@H](O)CO)C(Cl)=C3)=N/CCC

• Molecular Weight:

  465.00

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported